Outcomes of GLP-1 Receptor Agonist Therapy after Liver Transplantation in Patients with Type 2 Diabetes: A Real-World Cohort Study
Journal of Gastrointestinal and Liver Diseases · 2026
DOI: 10.15403/jgld-6863 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2026. Verfasst von Guy Loic Nguefang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Texas Tech University Health Sciences Center, Odessa, TX, United States. Guy.Nguefang@ttuhsc.edu. Hauptthemen laut MEDLINE: Liver Transplantation, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background and Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used to manage type 2 diabetes mellitus (T2DM) in liver transplant (LT) recipients, but their impact on graft outcomes remains unclear. This study evaluated clinical and graft-related outcomes associated with GLP-1 RA therapy.
Methods
We conducted a retrospective cohort study using the TriNetX Network, identifying adults with LT and T2DM. Two cohorts were defined: LT recipients treated with GLP-1 RAs and those receiving conventional antidiabetic therapy. Propensity score matching (1:1) was applied based on demographics, comorbidities, and immunosuppressive regimens. The index date was the first GLP-1 RA prescription within six months before or after LT. Outcomes assessed at one year included all-cause mortality, graft rejection, graft failure, biliary stricture, hepatic artery thrombosis, and transplant-related infections. Analyses used Kaplan–Meier survival curves and Cox proportional hazards models.
Results
After matching, 704 patients were included in each cohort. GLP-1 RA use was associated with significantly lower mortality (4.2% vs. 12.6%; HR=0.33, 95%CI: 0.22–0.50; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Texas Tech University Health Sciences Center, Odessa, TX, United States. Guy.Nguefang@ttuhsc.edu.
- Yale New Haven Health, Bridgeport Hospital, New Haven CT, United States. sarpong1500@gmail.com.
- Komfo Anokye Teaching Hospital, Kumasi, Ghana. solomongyabaah53@gmail.com.
- New York City Health and Hospitals South Brooklyn Health, Brooklyn, NY, United States. konlackjoel4@gmail.com.
- Yale New Haven Health, Bridgeport Hospital, New Haven CT, United States. yussifissaka2024@gmail.com.
- Texas Tech University Health Sciences Center, Odessa, TX, United States. elanda@ttuhsc.edu.
Zitieren
APA
Nguefang, G. L., Boateng, S., Gyabaah, S., Konlack, J. G., Issaka, Y., Luna Landa, E., Chukwu, T., Eze, E., & Njei, B. (2026). Outcomes of GLP-1 Receptor Agonist Therapy after Liver Transplantation in Patients with Type 2 Diabetes: A Real-World Cohort Study. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-6863
Vancouver
Nguefang GL, Boateng S, Gyabaah S, Konlack JG, Issaka Y, Luna Landa E, et al. Outcomes of GLP-1 Receptor Agonist Therapy after Liver Transplantation in Patients with Type 2 Diabetes: A Real-World Cohort Study. Journal of Gastrointestinal and Liver Diseases. 2026. doi:10.15403/jgld-6863
BibTeX
@article{Nguefang2026,
author = {Nguefang, Guy Loic and Boateng, Sarpong and Gyabaah, Solomon and Konlack, Joel Gabin and Issaka, Yussif and Luna Landa, Edgar and Chukwu, Tracy and Eze, Elvis and Njei, Basile},
title = {Outcomes of GLP-1 Receptor Agonist Therapy after Liver Transplantation in Patients with Type 2 Diabetes: A Real-World Cohort Study},
journal = {Journal of Gastrointestinal and Liver Diseases},
year = {2026},
doi = {10.15403/jgld-6863}
}
EUVIMED